Products

Introducing ZORYVE, a next generation PDE4i for plaque psoriasis.

ZORYVE brings meaningful innovation to the treatment of plaque psoriasis by simplifying disease management.1–3

About ZORYVE

ZORYVE is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age and older.

Important Safety Information

The use of ZORYVE is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C). 

The most common adverse reactions (≥1%) include diarrhea (3%), headache (2%), insomnia (1%), nausea (1%), application site pain (1%), upper respiratory tract infection (1%), and urinary tract infection (1%). 

Please see the full Prescribing Information for ZORYVE below.

For more information,
visit the ZORYVE website.

Arcutis is dedicated to affordable access to therapy.

Our commitment to solving today’s biggest medical dermatology challenges doesn’t stop at bringing new treatment options. There’s more to our Arcutis DNA. It’s why we believe in responsible pricing and helping patients get access to our product through ZORYVE Direct and our commercial co-pay program, the ZORYVE Direct savings program, as well as Arcutis Cares. 

The ZORYVE Direct patient access support program will help commercially insured individuals with plaque psoriasis get access and start ZORYVE treatment as prescribed by their healthcare provider quickly and easily by helping them navigate the payer process, lowering the out-of-pocket cost for eligible patients, and offering programs that support staying on therapy.

The Arcutis Cares patient assistance program (PAP) provides ZORYVE at no cost to eligible uninsured or underinsured patients with financial need.

Uninsured patients and patients with government insurance are not eligible for the ZORYVE Direct savings program. Other terms and restrictions apply.

Subject to financial eligibility requirements. Other terms and restrictions apply.

References

  1. ZORYVE. Prescribing Information. Arcutis Biotherapeutics, Inc; 2022. 
  2. Dong C, Virtucio C, Zemska O, et al. Treatment of skin inflammation with benzoxaborole phosphodiesterase inhibitors: Selectivity, cellular activity, and effect on cytokines associated with skin inflammation and skin architecture changes. J Pharmacol Exp Ther. 2016;358(3):413-422. 
  3. Data on file. Arcutis Biotherapeutics, Inc; 2021.

PDE4i = phosphodiesterase-4 inhibitor

CRP-ARQ-151-220004

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download